VIVUS (NASDAQ:VVUS) was downgraded by analysts at Piper Jaffray from a “neutral” rating to an “underweight” rating in a research report issued to clients and investors on Thursday, TheFlyOnTheWall.comreports. They currently have a $3.00 price objective on the stock, down from their previous price objective of $8.00. Piper Jaffray’s target price suggests a potential downside of 51.46% from the stock’s previous close. VIVUS, Inc. (NASDAQ:VVUS) shares after opening at $5.89 moved to $5.97 on last trade day and at the end of the day closed at $5.80. Company price to sales ratio in past twelve months was calculated as 7.39 and price to cash ratio as 1.75. VIVUS, Inc. (NASDAQ:VVUS) showed a negative weekly performance of 2.52%.
Investment analysts at Mizuho lifted their target price on shares of EXACT Sciences (NASDAQ:EXAS) from $18.00 to $22.00 in a note issued to investors on Friday, AnalystRatingsNetwork.com reports. Mizuho’s price target suggests a potential upside of 60.00% from the company’s current price. EXACT Sciences Corporation. (NASDAQ:EXAS) shares fell 9.33% in last trading session and ended the day on $12.92. EXACT Sciences Corporation. (NASDAQ:EXAS)return on equity ratio is recorded as -35.60% and its return on assets is -33.00%. EXACT Sciences Corporation. (NASDAQ:EXAS) yearly performance is 29.20%.
Celldex Therapeutics Inc. (NASDAQ: CLDX) has several pipeline immunotherapies, including rindopepimut, a Phase 3 immunotherapy that stimulates responses against specific types of brain tumor cells. One of the most exciting areas of drug development currently is the immuno-oncology space. Potential cancer cures and the multibillion dollar sales potential that coincide with these cures have raised company valuations and acquisition interest to obtain drugs in this category. This is another one of Jefferies’ top drug innovations for 2014. Celldex is Buy-rated at Jefferies, and the price target is $31. The consensus target is a whopping $36.33. Celldex closed Wednesday at $17.79. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares moved down 7.87% in last trading session and was closed at $16.39, while trading in range of $ 15.82 – 18.00. Celldex Therapeutics, Inc. (NASDAQ:CLDX) year to date (YTD) performance is -32.30%.
Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s shares increased 17.78% to $4.57. The company on Mar. 28 announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. The primary objective of the trial was to evaluate the safety and tolerability of IMO-8400 over a 12-week treatment period, with a secondary objective to evaluate the clinical activity of IMO-8400. The trial met its primary objective as all treatments were well tolerated with no treatment related discontinuation, serious adverse events or dose reductions. IMO-8400 treatment met the secondary objective of demonstrating clinical activity in patients with psoriasis, as assessed by Psoriasis Area and Severity Index (PASI). Idera Pharmaceuticals Inc. (NASDAQ:IDRA) weekly performance is 3.61%. On last trading day company shares ended up $4.02. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) distance from 50-day simple moving average (SMA50) is -21.13%. Analysts mean target Price for the company is $7.00.